{"search_session":{},"preferences":{"l":"en","queryLanguage":"en"},"patentId":"US_9365630_B2","frontPageModel":{"patentViewModel":{"ref":{"entityRefId":"026-533-598-883-19X","entityRefType":"PATENT"},"entityMetadata":{"linkedIds":{"empty":true},"tags":[],"collections":[{"id":11993,"type":"PATENT","title":"University of Connecticut Patent Portfolio","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":3197,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[{"id":8558,"type":"COLLECTION","user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"text":"
Search Applicants and Owners separately:Univ* Connecti*. Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 2880
Search Applicants and Owners separately:Univ* Connecti*. Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 2880
(a) a purified complex comprising an interleukin-15 (IL-15) polypeptide bound to a purified chimeric polypeptide comprising a soluble form of an IL-15 receptor alpha (IL-15Ra) polypeptide that is covalently linked to the Fc portion of an antibody; or\n
(b) a purified IL-15 polypeptide and a purified chimeric polypeptide comprising the soluble form of an IL-15Ra polypeptide that is covalently linked to the Fc portion of an antibody."],"number":1,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein the composition comprises a purified complex comprising an IL-15 polypeptide bound a purified chimeric polypeptide comprising a soluble form of an IL-15Ra polypeptide that is covalently linked to the Fc portion of an antibody."],"number":2,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein the composition comprises a purified IL-15 polypeptide and a purified chimeric polypeptide comprising the soluble form of an IL-15Ra polypeptide that is covalently linked to the Fc portion of an antibody."],"number":3,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 2, wherein the IL-15 polypeptide is:\n
(i) (a) encoded by a nucleic acid that is at least 80% identical to SEQ ID NO: 2 over the entire length of SEQ ID NO: 2; or (b) at least 95% identical to the amino acid sequence of SEQ ID NO: 6 over the length of the mature form of SEQ ID NO: 6; and\n
(ii) capable of forming a complex with IL-15Ra polypeptide."],"number":4,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 2, wherein the IL-15 polypeptide has the amino acid sequence of SEQ ID NO: 6."],"number":5,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 2, wherein the soluble form of the IL-15Ra polypeptide is:\n
(i) a soluble form of an IL-15Ra polypeptide and the IL-15Ra polypeptide is (a) encoded by a nucleic acid that is at least 80% identical to SEQ ID NO: 4 over the entire length of SEQ ID NO: 4; or (b) at least 95% identical to the amino acid sequence of SEQ ID NO: 8 over the length of the mature form of SEQ ID NO: 8; and\n
(ii) capable of forming a complex with IL-15 polypeptide."],"number":6,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 2, wherein the soluble form of the IL-15Ra polypeptide:\n
(i) has the amino acid sequence of the extracellular domain of an IL-15Ra polypeptide and the IL-15Ra polypeptide is (a) encoded by a nucleic acid that is at least 80% identical to SEQ ID NO: 4 over the entire length of SEQ ID NO: 4; or (b) at least 95% identical to the amino acid sequence of SEQ ID NO: 8 over the length of the mature form of SEQ ID NO: 8; and\n
(ii) is capable of forming a complex with IL-15 polypeptide."],"number":7,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 6, wherein the IL-15Ra polypeptide has the amino acid sequence of SEQ ID NO: 8."],"number":8,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 7, wherein the IL-15Ra polypeptide has the amino acid sequence of SEQ ID NO: 8."],"number":9,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 4, wherein the soluble form of the IL-15Ra polypeptide is:\n
(i) a soluble form of an IL-15Ra polypeptide and the IL-15Ra polypeptide is (a) encoded by a nucleic acid that is at least 80% identical to SEQ ID NO: 4 over the entire length of SEQ ID NO: 4; or (b) at least 95% identical to the amino acid sequence of SEQ ID NO: 8 over the length of the mature form of SEQ ID NO: 8; and\n
(ii) capable of forming a complex with IL-15 polypeptide."],"number":10,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 4, wherein the soluble form of the IL-15Ra polypeptide:\n
(i) has the amino acid sequence of the extracellular domain of an IL-15Ra polypeptide and the IL-15Ra polypeptide is (a) encoded by a nucleic acid that is at least 80% identical to SEQ ID NO: 4 over the entire length of SEQ ID NO: 4; or (b) at least 95% identical to the amino acid sequence of SEQ ID NO: 8 over the length of the mature form of SEQ ID NO: 8; and\n
(ii) is capable of forming a complex with IL-15 polypeptide."],"number":11,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 10, wherein the IL-15Ra polypeptide has the amino acid sequence of SEQ ID NO: 8."],"number":12,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 11, wherein the IL-15Ra polypeptide has the amino acid sequence of SEQ ID NO: 8."],"number":13,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 5, wherein the soluble form of the IL-15Ra polypeptide is:\n
(i) a soluble form of an IL-15Ra polypeptide and the IL-15Ra polypeptide is (a) encoded by a nucleic acid that is at least 80% identical to SEQ ID NO: 4 over the entire length of SEQ ID NO: 4; or (b) at least 95% identical to the amino acid sequence of SEQ ID NO: 8 over the length of the mature form of SEQ ID NO: 8; and\n
(ii) capable of forming a complex with IL-15 polypeptide."],"number":14,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 5, wherein the soluble form of the IL-15Ra polypeptide:\n
(i) has the amino acid sequence of the extracellular domain of an IL-15Ra polypeptide and the IL-15Ra polypeptide is (a) encoded by a nucleic acid that is at least 80% identical to SEQ ID NO: 4 over the entire length of SEQ ID NO: 4; or (b) at least 95% identical to the amino acid sequence of SEQ ID NO: 8 over the length of the mature form of SEQ ID NO: 8; and\n
(ii) is capable of forming a complex with IL-15 polypeptide."],"number":15,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 14, wherein the IL-15Ra polypeptide has the amino acid sequence of SEQ ID NO: 8."],"number":16,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 15, wherein the IL-15Ra polypeptide has the amino acid sequence of SEQ ID NO: 8."],"number":17,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 2, wherein the composition is administered by a parenteral route."],"number":18,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 2, wherein the composition is administered by an intravenous route, subcutaneous route or intramuscular route."],"number":19,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 2, wherein the cancer is lymphoma."],"number":20,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 2, wherein the cancer is leukemia."],"number":21,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 2, wherein the cancer is prostate cancer, uterus cancer, liver cancer, melanoma, neoplasm, adenocarcinoma, lung cancer, kidney cancer or pancreatic cancer."],"number":22,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 2, wherein the human is lymphopenic."],"number":23,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 2, which further comprises administering another active ingredient to the human."],"number":24,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 24, wherein the active ingredient is anti-oncogenic."],"number":25,"annotation":false,"claim":true,"title":false}]}},"filters":{"npl":[],"notNpl":[],"applicant":[],"notApplicant":[],"inventor":[],"notInventor":[],"owner":[],"notOwner":[],"tags":[],"dates":[],"types":[],"notTypes":[],"j":[],"notJ":[],"fj":[],"notFj":[],"classIpcr":[],"notClassIpcr":[],"classNat":[],"notClassNat":[],"classCpc":[],"notClassCpc":[],"so":[],"notSo":[],"sat":[]},"sequenceFilters":{"s":"SEQIDNO","d":"ASCENDING","p":0,"n":10,"sp":[],"si":[],"len":[],"t":[],"loc":[]}}